

Mozobil[®] (plerixafor) – First-time authorized brand alternative

- On July 11, 2023, Fresenius Kabi launched an authorized brand alternative of Sanofi/Genzyme's [Mozobil \(plerixafor\)](#) subcutaneous solution.
- Mozobil is approved in combination with granulocyte-colony stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma or multiple myeloma.